JHP Pharmaceuticals to Produce Lyophilized Biologic
JHP Pharmaceuticals recently announced it has entered into an agreement with an undisclosed pharmaceutical company to produce supplies of a lyophilized biologic for international, late-phase clinical trials.
“We know that customers want to seamlessly progress from clinical batch production to product launch and then commercialization,” said Stuart Hinchen President and CEO of JHP. “JHP’s established infrastructure and expertise transitioning products from clinical to commercial supply are recognized by customers looking for long-term reliability and continuity when selecting a contract manufacturing organization. Additionally, our cGMP compliance record and experienced staff allows customers to focus on their pressing business needs with confidence.”
JHP has successfully supported launches of several products in US and international markets and manufactures products for sale in 86 countries. JHP’s Rochester, MI, manufacturing site’s 25-year history in contract manufacturing is a result of a solid cGMP compliance record, a quality-driven experienced staff and a customer-centric approach.
JHP Pharmaceuticals, headquartered in NJ, provides contract manufacturing of sterile products, including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics, and antibiotics for large and small pharmaceutical and biotech organizations. For more information, visit www.jhppharma.com.
Total Page Views: 1007
